AN OPEN-LABELLED RANDOMISED COMPARATIVE EVALUATION OF THERAPEUTIC EFFICACY AND SAFETY OF APREMILAST VERSUS METHOTREXATE IN THE TREATMENT OF PATIENTS WITH CHRONIC PLAQUE PSORIASIS

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year

10.1016/j.jaad.2021.06.263 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB59

Author(s):

Christine Bodemer ◽

Andrzej Kaszuba ◽

Külli Kingo ◽

Athanasios Tsianakas ◽

Akimichi Morita ◽

...

Keyword(s):

Plaque Psoriasis ◽

Safety Profile ◽

Pediatric Patients ◽

Efficacy And Safety ◽

Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis

American Journal of Clinical Dermatology ◽

10.2165/11539780-000000000-00000 ◽

2011 ◽

Vol 12 (3) ◽

pp. 191-201 ◽

Cited By ~ 10

Author(s):

Luigi Naldi ◽

Nikhil Yawalkar ◽

Andrzej Kaszuba ◽

Jean-Paul Ortonne ◽

Paolo Morelli ◽

...

Keyword(s):

Plaque Psoriasis ◽

Betamethasone Valerate ◽

Efficacy And Safety ◽

Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet: Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-Blind Trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/j.yder.2011.11.013 ◽

2012 ◽

Vol 2012 ◽

pp. 111-113

Author(s):

B.D. Michaels ◽

J.Q. Del Rosso

Keyword(s):

Plaque Psoriasis ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Blind Trial ◽

Hands And Feet

Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis

10.1016/j.jaad.2004.10.710 ◽

2005 ◽

Vol 52 (3) ◽

pp. P174

Keyword(s):

Psoriatic Arthritis ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

The Journal of Dermatology ◽

10.1111/j.1346-8138.2009.00748.x ◽

2010 ◽

Vol 37 (4) ◽

pp. 299-310 ◽

Cited By ~ 121

Author(s):

Akihiko ASAHINA ◽

Hidemi NAKAGAWA ◽

Takafumi ETOH ◽

Mamitaro OHTSUKI ◽

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Efficacy And Safety ◽

Randomized Controlled

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

British Journal of Dermatology ◽

10.1111/j.1365-2133.2010.10139.x ◽

2011 ◽

Vol 164 (2) ◽

pp. 434-441 ◽

Cited By ~ 72

Author(s):

K. Papp ◽

J. Crowley ◽

J.-P. Ortonne ◽

J. Leu ◽

M. Okun ◽

...

Keyword(s):

Plaque Psoriasis ◽

Disease Recurrence ◽

Efficacy And Safety ◽

Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results

10.1016/j.jaad.2004.10.020 ◽

2005 ◽

Vol 52 (3) ◽

pp. P1

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Final Phase ◽

Study Results ◽

Phase Iiib

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/j.yder.2011.09.022 ◽

2012 ◽

Vol 2012 ◽

pp. 107-108

Author(s):

J. Weinberg

Keyword(s):

Plaque Psoriasis ◽

Disease Recurrence ◽

Efficacy And Safety ◽